View Item 

Show simple item record

Institutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropenia

dc.contributor.authorShehab, Nadineen_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorMackler, Emily R.en_US
dc.contributor.authorCollins, Curtis D.en_US
dc.contributor.authorWelch, Kathleenen_US
dc.contributor.authorErba, Harry P.en_US
dc.date.accessioned2012-03-16T15:52:51Z
dc.date.available2012-03-16T15:52:51Z
dc.date.issued2007-07en_US
dc.identifier.citationShehab, Nadine; DePestel, Daryl D.; Mackler, Emily R.; Collins, Curtis D.; Welch, Kathleen; Erba, Harry P. (2007). "Institutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropenia." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27(7). <http://hdl.handle.net/2027.42/90034>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90034
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherVoriconazoleen_US
dc.subject.otherL‐AmBen_US
dc.subject.otherFebrile Neutropeniaen_US
dc.subject.otherAntifungalsen_US
dc.subject.otherHematologyen_US
dc.subject.otherEmpiric Therapyen_US
dc.subject.otherLiposomal Amphotericin Ben_US
dc.titleInstitutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropeniaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCenter for Statistical Consultation and Research, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology‐Oncology, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartment of Clinical Sciences, College of Pharmacy, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartment of Internal Medicine, School of Medicine, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.identifier.pmid17594202en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90034/1/phco.27.7.970.pdf
dc.identifier.doi10.1592/phco.27.7.970en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceWinston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282 – 9.en_US
dc.identifier.citedreferenceAscioglu S., Rex JH, de Pauw B, et al, for the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7 – 14.en_US
dc.identifier.citedreferenceDonowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient: new views of an old problem. Hematology (Am Soc Hematol Educ Program) 2001; 113 – 39.en_US
dc.identifier.citedreferenceKlastersky J.. Empirical antifungal therapy. Int J Antimicrob Agents 2004; 23: 105 – 12.en_US
dc.identifier.citedreferenceMartino P., Girmenia C.. Making the diagnosis of fungal infection: when to start treatment. Int J Antimicrob Agents 2000; 16: 323 – 9.en_US
dc.identifier.citedreferenceMarr KA. Empirical antifungal therapy: new options, new tradeoffs [editorial]. N Engl J Med 2002; 346: 278 – 80.en_US
dc.identifier.citedreferencePowers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever [comment]. N Engl J Med 2002; 346: 289 – 90.en_US
dc.identifier.citedreferenceJohnson JR. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy [comment]. N Engl J Med 2002; 346: 1745 – 7.en_US
dc.identifier.citedreferenceElting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 2002; 10: 189 – 96.en_US
dc.identifier.citedreferenceDanaher PJ. Caspofungin versus liposomal amphotericin B for empirical therapy [comment]. N Engl J Med 2005; 352: 410 – 14.en_US
dc.identifier.citedreferenceJorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;( 1 ): CD004707.en_US
dc.identifier.citedreferencePizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101 – 11.en_US
dc.identifier.citedreferenceEORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668 – 72.en_US
dc.identifier.citedreferenceSchneemann M., Imhof A.. Caspofungin versus liposomal amphotericin B for empirical therapy [comment]. N Engl J Med 2005; 352: 410 – 14.en_US
dc.identifier.citedreferenceViscoli C., Castagnola E., Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32: 814 – 20.en_US
dc.identifier.citedreferenceMalik IA, Moid I., Aziz Z., Khan S., Suleman M.. A randomized comparison of fluconazole with amphotericin B as empiric anti‐fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105: 478 – 83.en_US
dc.identifier.citedreferenceWhite MH, Bowden RA, Sandler ES, et al. Randomized, double‐blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296 – 302.en_US
dc.identifier.citedreferenceCagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476 – 83.en_US
dc.identifier.citedreferenceBoogaerts M., Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad‐spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135: 412 – 22.en_US
dc.identifier.citedreferenceWalsh TJ, Teppler H., Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391 – 402.en_US
dc.identifier.citedreferenceX‐GEN Pharmaceuticals Inc. Amphotericin B for injection package insert. Northport, NY; 2003.en_US
dc.identifier.citedreferenceFujisawa Healthcare, Inc. AmBisome (amphotericin B) liposome for injection package insert. Deerfield, IL; 2002.en_US
dc.identifier.citedreferenceOrtho Biotech. Sporanox (itraconazole) injection package insert. North Chicago, IL; 2004.en_US
dc.identifier.citedreferenceMerck & Co, Inc. Cancidas (caspofungin acetate) for injection package insert. Whitehouse Station, NJ; 2005.en_US
dc.identifier.citedreferencePowers JH. Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values [comment]. Clin Infect Dis 2004; 39: 1738 – 9.en_US
dc.identifier.citedreferenceKullberg BJ, Sobel JD, Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non‐neutropenic patients: a randomised non‐inferiority trial. Lancet 2005; 366: 1435 – 42.en_US
dc.identifier.citedreferenceGrimshaw JM, Russell JT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317 – 22.en_US
dc.identifier.citedreferenceKauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588 – 90.en_US
dc.identifier.citedreferenceKlastersky J., Paesmans M., Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low‐risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038 – 51.en_US
dc.identifier.citedreferenceBennett JE, Powers J., Walsh T., et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 15 ( 36 suppl 3): S117 – 22.en_US
dc.identifier.citedreferenceHoenig JM, Heisery DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat 2001; 55: 19 – 24.en_US
dc.identifier.citedreferenceLevine M., Ensom MHH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001; 21: 405 – 9.en_US
dc.identifier.citedreferenceHughes WT, Armstrong D., Bodey GP, et al, for the Infectious Diseases Society of America. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730 – 51.en_US
dc.identifier.citedreferenceWalsh TJ, Finberg RW, Arndt C, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764 – 71.en_US
dc.identifier.citedreferenceWingard JR, White M., Anaissie E., Raffalli J., Goodman J., Arrieta A, for the L Amph/ABLC Collaborative Study Group. A randomized, double‐blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155 – 63.en_US
dc.identifier.citedreferenceWalsh TJ, Pappas P., Winston DJ, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225 – 34.en_US
dc.identifier.citedreferenceEspinel‐Ingroff A.. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954 – 8.en_US
dc.identifier.citedreferenceKappe R.. Antifungal activity of the new azole UK‐109, 496 (voriconazole). Mycoses 1999; 42 ( suppl 2 ): 83 – 6.en_US
dc.identifier.citedreferenceHoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999; 43: 1463 – 4.en_US
dc.identifier.citedreferenceAlly R., Schurmann D., Kreisel W, et al, for the Esophageal Candidiasis Study Group. A randomized, double‐blind, double‐dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447 – 54.en_US
dc.identifier.citedreferenceDenning DW, Ribaud P., Milipied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563 – 71.en_US
dc.identifier.citedreferenceHerbrecht R., Denning DW, Patterson TF, et al, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408 – 15.en_US
dc.identifier.citedreferencePfizer, Inc. Vfend (voriconazole) package insert. New York, NY; 2003.en_US
dc.identifier.citedreferenceCohen HE, ed. Drug topics red book. Montvale, NJ: Medical Economics Company, 2003.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.27.7.970.pdf
Size:
96.71KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.